Boundless Bio (NASDAQ:BOLD) said it has received clearance from the Food and Drug Administration for its investigational new ...

The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.

After a cacophony of troubles hit the RNA editing biotech last fall, CEO Ram Aiyar is in San Francisco to develop ...

Instil Bio said its subsidiary has discontinued clinical development of AXN-2510 and terminated its collaboration agreement with ImmuneOnco Biopharmaceuticals (Shanghai) for AXN-2510 and AXN-27M.

Jan 6 () - Variant Bio, a private biotech firm, said on Tuesday it has launched a platform that ​uses artificial intelligence on genetic data to discover new ‌drug candidates to send into human trials ...

The collaboration will leverage Abalone Bio’s Functional Antibody Selection Technology platform for an undisclosed ...

Accelerated drug discovery and development platform Converge Bio Inc. today announced it has raised $25 million in ...

Every small business owner should have a short, succinct bio that can be used for various purposes. The bio should be authoritative and positive, and should reflect your level of professional ...

Learn how spectroscopy facilitates non-invasive, real-time bio-monitoring, enhancing decision-making in healthcare, ...